# US 2026/0083749 A1 · Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083749 A1
- Document ID: US20260083749A1
- Status: Published application
- Kind: A1
- Application number: 19/204,211
- Filed: 2025-05-09
- Published: 2026-03-26
- Earliest claimed: 2024-05-10
- Assignees: ImmunoGen, Inc.
- Applicants: ImmunoGen, Inc.
- Inventors: Patrick Zweidler-McKay
- Web page: https://patentgrep.com/patent/US20260083749A1

## CPC

- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6845: {the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}
- A61P 35/02: specific for leukemia
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods and uses of immunoconjugates that bind to CD123 (e.g., pivekimab sunirine) in patients with acute myeloid leukemia (AML) are provided. Such immunoconjugates can be used as monotherapies or can be used in combination with BCL-2 inhibitors (e.g., venetoclax), and/or hypomethylating agents (e.g., azacitidine or decitabine) to prepare patients with AML for hematopoietic stem cell transplant and/or to achieve complete remissions in patients with AML, including those with poor prognostic markers.

## Claims

### Claim 1

A method of treating an unfit newly diagnosed acute myeloid leukemia (ND AML) in a subject comprising administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent.

### Claim 2

A method for treating an acute myeloid leukemia (AML) in a subject comprising administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent, wherein the administration achieves a complete response (CR), CR (clinical) with partial hematological recovery (CRh), CR with incomplete platelet recovery (CRp), or CR (clinical) with incomplete recovery (CRi) with a duration of at least 3 months.

### Claim 3

A method for treating a FLT3 TKD, IDH1mut, NMP1mut, and/or K/NASmut acute myeloid leukemia (AML) in a subject with comprising administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent.

### Claim 4

A method of clearing minimal residual disease (MRD) in a human subject with acute myeloid leukemia (AML) comprising administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent, wherein the MRD is cleared in 2 months or less.

### Claim 5 (depends on 1, 3)

The method of any one of claims 1, 3, and 4, wherein the administration of the combination therapy achieves a complete response with a duration of at least 3 months.

### Claim 6 (depends on 2, 5)

The method of claim 2 or 5, wherein the duration of the CR, CRh, CRp, or CRi is at least 4 months.

### Claim 7 (depends on 2, 5)

The method of claim 2 or 5, wherein the duration of the CR, CRh, CRp, or CRi is at least 5 months or at least 6 months.

### Claim 8 (depends on 2, 5)

The method of claim 2 or 5, wherein the duration of the CR, CRh, CRp, or CRi is at least 10 months or at least 12 months.

### Claim 9 (depends on 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 2-8, wherein the AML is unfit ND AML.

### Claim 10 (depends on 1, 2)

The method of any one of claims 1, 2, and 4-9, wherein the ND AML is a FLT3 TKD, IDH1mut, NMP1mut and/or K/NASmut AML.

### Claim 11 (depends on 1, 2, 3, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-3 and 5-10, wherein the administration of the combination therapy achieves a minimal residual disease (MRD)-negative status in 2 months or less.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the method further comprises administering a hematopoietic stem cell transplant (HSCT) to the subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein the HSCT is allogeneic.

### Claim 14 (depends on 12)

The method of claim 12, wherein the HSCT is autologous.

### Claim 15 (depends on 12, 13, 14)

The method of any one of claims 12-14, wherein the HSCT is administered about 4 to about 8 weeks after the administration of pivekimab sunirine.

### Claim 16

A method of preparing a subject with acute myeloid leukemia (AML) for a hematopoietic stem cell transplant (HSCT), the method comprising administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent.

### Claim 17

A method for treating an acute myeloid leukemia (AML) in a subject comprising (i) administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent and (ii) subsequently administering a hematopoietic stem cell transplant (HSCT) to the subject.

### Claim 18

A method for treating an acute myeloid leukemia (AML) in a subject comprising administering a hematopoietic stem cell transplant (HSCT) to the subject, wherein the subject has previously been treated with pivekimab sunirine.

### Claim 19 (depends on 16, 17, 18)

The method of any one of claims 16-18, wherein the HSCT is allogeneic.

### Claim 20 (depends on 16, 17, 18)

The method of any one of claims 16-18, wherein the HSCT is autologous.

### Claim 21 (depends on 16, 17, 18, 19, 20)

The method of any one of claims 16-20, wherein the HSCT is administered about 4 to about 8 weeks after the administration of pivekimab sunirine.

### Claim 22 (depends on 16, 17, 18, 19, 20, 21)

The method of any one of claims 16-21, wherein the administration achieves a minimal residual disease (MRD)-negative status.

### Claim 23 (depends on 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 16-22, wherein the AML is a FLT3 TKD, IDH1mut, NMP1mut, and/or K/NASmut AML.

### Claim 24 (depends on 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 16-23, wherein the pivekimab sunirine is administered once every three weeks (Q3W).

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1-24, wherein the administration of the combination therapy results in survival for at least 3 months.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1-24, wherein the administration of the combination therapy results in survival for at least 6 months.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the administration of the combination therapy achieves undetectable disease.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the administration of the combination therapy results in a pivekimab sunirine Cmax of about 400 to about 600 ng/mL after a single administration of the pivekimab sunirine and/or a pivekimab sunirine Cmax of about 550 to 700 ng/mL after three administrations of the pivekimab sunirine.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1-28, wherein the administration of the combination therapy results in a pivekimab sunirine AUCINF of about 4,500 to about 5,000 h*ng/mL after a single administration of the pivekimab sunirine and/or a pivekimab sunirine AUCINF of about 4,750 to about 5,250 h*ng/mL after three administrations of the pivekimab sunirine.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the administration of the combination therapy results in no more than 30% CD123 receptor availability 4 hours after administration of the pivekimab sunirine.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the AML is a TP53WT AML.

### Claim 32 (depends on 31)

The method of claim 31, wherein the AML is a K/NRASWT AML with no FLT3-ITD.

### Claim 33 (depends on 31)

The method of claim 31, wherein the AML is a FLT3-ITD or K/NRASmut AML.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the AML is a TP53mut AML.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the AML is a FLT3 ITD or TKD, IDH1mut, IDH2mut, NPM1mut, and/or K/NRASmut AML.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the subject has a baseline mutation in RUNX1, ASXL1, or TP53.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein the AML has a favorable ELN 2017 risk.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein the AML has an intermediate ELN 2017 risk.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein the AML has an adverse ELN 2017 risk.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 1-39, wherein the subject was previously treated with an anti-CD123 therapy, optionally wherein the anti-CD123 therapy was tagraxofusp (SL-401).

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 1-39, wherein the subject has not received tagraxofusp (SL-401) prior to the administration of the combination therapy.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 1-41, wherein the AML expresses multidrug resistance 1 (MDR1).

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 1-42, wherein the AML expresses P-glycoprotein (P-gp).

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 1-43, wherein the subject has an absolute neutrophil count of greater than 500/L (microliter).

### Claim 45 (depends on 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 2, 3-8, and 10-44, wherein the AML is unfit AML.

### Claim 46 (depends on 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 2, 3-8, and 10-44, wherein the AML is fit AML.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 1-46, wherein the cancer has previously been treated with venetoclax.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 1-46, wherein the cancer has not previously been treated with venetoclax.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 1-48, wherein the cancer has previously been treated with a hypomethylating agent.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 1-48, wherein the cancer has not previously been treated with a hypomethylating agent.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 1-50, wherein the subject received a stem cell transplant prior to the administration of the combination therapy.

### Claim 52 (depends on 51)

The method of claim 51, wherein the stem cell transplant was received at least 120 days prior to the administration.

### Claim 53 (depends on 51, 52)

The method of claim 51 or 52, wherein the previous stem cell transplant was allogeneic.

### Claim 54 (depends on 51, 52)

The method of claim 51 or 52, wherein the previous stem cell transplant was autologous.

### Claim 55 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 16-54, wherein the AML is a relapsed and/or refractory AML.

### Claim 56 (depends on 55)

The method of claim 55, wherein the AML is a relapsed AML.

### Claim 57 (depends on 55)

The method of claim 55, wherein the AML is a refractory AML.

### Claim 58 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 16-57, wherein the subject received at least one prior line of therapy, at least two prior lines of therapy, or at least three prior lines of therapy.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, and 25-54 wherein the administration of the combination therapy is a frontline therapy.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the AML is de novo AML.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the subject has a prior or concomitant hematologic malignancy (PCHM).

### Claim 62 (depends on 61)

The method of claim 61, wherein the PCHM does not require immediate therapy.

### Claim 63 (depends on 61, 62)

The method of claim 61 or 62, wherein the PCHM is in remission and the subject has completed all therapies for the PCHM at least 6 months prior to the administration of the combination therapy.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 1-63, wherein the subject has not received immunosuppressive treatment for at least 14 days prior to the administration of the combination therapy.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 1-64, wherein the subject has not received a systemic anti-cancer therapy for at least 14 days prior to the administration of the combination therapy.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 1-64, wherein the subject has received a local therapy at least 14 days prior to the administration of the combination therapy.

### Claim 67 (depends on 66)

The method of claim 66, wherein the therapy was radiotherapy.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claim 1-67, wherein the method further comprises administration of ursodeoxycholic acid.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 1-68, wherein the subject has liver enzymes less than or equal to 2.5× the upper limit of normal, total bilirubin less than or equal to 1.5× the upper limit of normal, glomerular filtration rate of greater than 30 mL/min/1.73 m2 or creatinine clearance of greater than 30 mL/min, and left ventricular ejection fraction of greater than or equal to 45%.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of claims 1-69, wherein the pivekimab sunirine is administered intravenously.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 1-70, wherein the pivekimab sunirine is administered by a controlled rate of infusion.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 1-71, wherein the pivekimab sunirine is administered in an infusion having a duration of no more than 30 minutes.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 1-72, wherein the pivekimab sunirine is administered in an infusion having a duration of about 15 to 30 minutes.

### Claim 74 (depends on 71, 72, 73)

The method of any one of claims 71-73, wherein the controlled rate of infusion is from about 0.8 m/min to about 1.7 mL/min.

### Claim 75 (depends on 71, 72, 73)

The method of any one of claims 71-73, wherein the controlled rate of infusion is about 0.8 mL/min (about 50 mL/hour or about 0.165 mg/min) for the first 30 minutes.

### Claim 76 (depends on 71, 72, 73, 74)

The method of any one of claims 71-74, wherein the controlled rate of infusion is increased to about 1.7 mL/min (about 100 mL/hour or about 0.33 mg/min).

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any one of claims 1-76, wherein the pivekimab sunirine is administered at a dose of about 0.045 mg/kg.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the pivekimab sunirine is administered once every 4 weeks (Q4W).

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78)

The method of any one of claims 1-15 or 78, wherein the BCL-2 inhibitor is administered daily for at least 14 days of a 28-day cycle.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78)

The method of any one of claims 1-15 or 78, wherein the BCL-2 inhibitor is administered daily for up to 28 days of a 28-day cycle.

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78, 79, 80)

The method of any one of claims 1-15 or 78-80, wherein the BCL-2 inhibitor is administered at a dose of up to about 400 mg.

### Claim 82 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78, 79, 80, 81)

The method of any one of claims 1-15 or 78-81, wherein the BCL-2 inhibitor is administered orally.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78, 79, 80, 81, 82)

The method of any one of claims 1-15 or 78-82, wherein the BCL-2 inhibitor is venetoclax.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78, 79, 80, 81, 82, 83)

The method of any one of claims 1-15 or 78-83, wherein the hypomethylating agent is administered daily for days 1-7 of a 28-day cycle.

### Claim 85 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78, 79, 80, 81, 82, 83, 84)

The method of any one of claims 1-15 or 78-84, wherein the hypomethylating agent is administered at a dose of about 75 mg/m2.

### Claim 86 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78, 79, 80, 81, 82, 83, 84, 85)

The method of any one of claims 1-15 or 78-85, wherein the hypomethylating agent is administered subcutaneously or intravenously.

### Claim 87 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The method of any one of claims 1-15 or 78-86, wherein the hypomethylating agent is azacitidine.

### Claim 88 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The method of any one of claims 1-15 or 78-86, wherein the hypomethylating agent is decitabine.

### Claim 89 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The method of any one of claims 1-15 or 78-88, wherein the pivekimab sunirine is administered at a dose of 0.045 mg/kg intravenously on day 7; the hypomethylating agent is azacitidine and it is administered at a dose of 75 mg/m2 subcutaneously or intravenously on days 1-7, and the BCL-2 inhibitor is venetoclax and it is administered at a dose of 400 mg orally for at least 14 days.

### Claim 90 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The method of any one of claims 1-15 or 78-88, wherein the pivekimab sunirine is administered at a dose of 0.045 mg/kg intravenously on day 7; the hypomethylating agent is azacitidine and it is administered at a dose of 75 mg/m2 subcutaneously or intravenously on days 1-7, and the BCL-2 inhibitor is venetoclax and it is administered at a dose of 400 mg orally for up to 28 days.

### Claim 91 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The method of any one of claims 1-90, wherein the administration is for one cycle.

### Claim 92 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The method of any one of claims 1-90, wherein the administration is for more than one cycle, optionally wherein the administration is for at least 2 cycles, at least 3 cycles, at least 4 cycles, at least 5 cycles, at least 6 cycles, at least 7 cycles, at least 8 cycles, at least 9 cycles, or at least 10 cycles or wherein the administration is for about 2-4 cycles, about 2-6 cycles, about 2-8 cycles, about 2-10 cycles, or about 2-12 cycles.

### Claim 93 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The method of any one of claims 1-92, wherein the method further comprises administering a reduced dose of the pivekimab sunirine after a dose-limiting toxicity has occurred in the subject and has been reduced to baseline or ≤Grade 2.

### Claim 94 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The method of any one of claims 1-93, wherein the AML is CD123-positive.

### Claim 95 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The method of any one of claims 1-94, wherein CD123 has been detected in a sample obtained from the AML prior to the administration of the combination therapy, optionally wherein the CD123 was detected using flow cytometry or immunohistochemistry.

### Claim 96 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The method of any one of claims 1-95, further comprising detecting CD123 in a sample obtained from the AML prior to the administration of the combination therapy.

### Claim 97 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 1-96, wherein at least 80% of cells in the AML express CD123.

### Claim 98 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any one of claims 1-97, wherein CD123 has been detected in at least 80% of cells in a sample obtained from the AML prior to the administration of the combination therapy.

### Claim 99 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method of any one of claims 1-98, further comprising detecting CD123 in at least 80% of cells in a sample obtained from the AML prior to the administration of the combination therapy.

### Claim 100 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The method of any one of claims 1-99, wherein the subject is not selected based on level of CD123 expression.

### Claim 101 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The method of any one of claims 1-100, wherein the subject has been pretreated with a premedication or corticosteroid prior to administration of the pivekimab sunirine, optionally wherein the premedication or corticosteroid is diphenhydramine, acetaminophen, paracetamol, dexamethasone, or a combination thereof.

### Claim 102 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The method of any one of claims 1-100, further comprising pre-treating the subject with a premedication or corticosteroid prior to administration of the pivekimab sunirine, optionally wherein the premedication or corticosteroid is diphenhydramine, acetaminophen, paracetamol, dexamethasone, or a combination thereof.

### Claim 103 (depends on 101, 102)

The method of any one of claims 101-102, wherein the corticosteroid is administered to a patient on the day prior and once, prior to and on the same day as administering an anti-CD123 immunoconjugate, e.g., pivekimab sunirine, to the patient.

### Claim 104 (depends on 101, 102)

The method of any one of claims 101-102, wherein the corticosteroid is administered to a patient twice on the day prior and once, prior to and on the same day as administering an anti-CD123 immunoconjugate, e.g., pivekimab sunirine, to the patient.

### Claim 105 (depends on 101, 102, 103, 104)

The method of any one of claims 101-104, wherein the corticosteroid is dexamethasone.

### Claim 106 (depends on 105)

The method of claim 105, wherein the dexamethasone is administered at a dose of 8 mg or 10 mg.

### Claim 107 (depends on 101, 102, 103, 104, 105, 106)

The method of any one of claims 101-106, wherein the subject is further premedicated with an antihistamine and an antipyretic at least 30 minutes prior to dosing with pivekimab sunirine anti-CD123 immunoconjugate.

### Claim 108 (depends on 107)

The method of claim 107, wherein the antihistamine is diphenhydramine and the antipyretic is acetaminophen or paracetamol.

### Claim 109 (depends on 108)

The method of claim 108, wherein diphenhydramine is administered intravenously at a dose of 25 mg to 50 mg; and (i) acetaminophen is administered orally or intravenously at a dose of 325 mg to 650 mg or (ii) paracetamol is administered orally or intravenously at a dose of 500 mg to 1000 mg.

### Claim 110

A method of treating an unfit newly diagnosed acute myeloid leukemia (ND AML) in a subject comprising administering to the subject (i) 0.045 mg/kg pivekimab sunirine, (ii) venetoclax, and (iii) azacitidine, wherein the administration achieves a complete response (CR), CR (clinical) with partial hematological recovery (CRh), CR with incomplete platelet recovery (CRp), or CR (clinical) with incomplete recovery (CRi) with a duration of at least 3 months.

### Claim 111 (depends on 110)

The method of claim 110, wherein the AML is a FLT3 TKD, IDH1mut, NMP1mut, and/or K/NASmut AML.

### Claim 112 (depends on 110, 111)

The method of claim 110 or 111, wherein the pivekimab sunirine is administered on day 7 of a 28 day cycle; the is azacitidine and it is administered at a dose of 75 mg/m2 on days 1-7 of the cycle, and the venetoclax is administered at a dose of 400 mg for at least 14 days of the cycle.

### Claim 113 (depends on 110, 111)

The method of claim 110 or 111, wherein the pivekimab sunirine is administered on day 7 of a 28 day cycle; the is azacitidine and it is administered at a dose of 75 mg/m2 on days 1-7 of the cycle, and the venetoclax is administered at a dose of 400 mg for up to 28 days of the cycle.

### Claim 114

A method of treating relapsed and/or refractory AML in a subject comprising administering to the subject (i) 0.045 mg/kg pivekimab sunirine, (ii) venetoclax, and (iii) azacitidine, wherein the administration achieves a complete response (CR), CR (clinical) with partial hematological recovery (CRh) or CR (clinical) with incomplete recovery (CRi) complete response with a duration of at least 2 months.

### Claim 115 (depends on 1, 114)

Use of pivekimab sunirine in the method of any one of claims 1-114 or in the preparation for a medicament for use in the method of any one of claims 1-114.
